|Bid||2.3100 x N/A|
|Ask||2.3400 x N/A|
|Day's range||2.3000 - 2.4300|
|52-week range||2.2100 - 6.9000|
|Beta (5Y monthly)||2.42|
|PE ratio (TTM)||N/A|
|Earnings date||26 Jul 2023 - 31 Jul 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Tilray Brands' (NASDAQ: TLRY) stock price is down around 60% over the past year. Is the stock due for some downgrades, or has Tilray reached such a low value that there's a lot of upside for the stock at its current price? Most price targets are set at $3.50 and higher -- roughly double where Tilray's stock is today.
It's safe to say that no one caught a pleasant buzz from Tilray Brands (NASDAQ: TLRY) stock on Friday. After market hours on Thursday, the ever cash-strapped Tilray announced it had launched a registered offering of $150 million worth of convertible senior notes. The notes are convertible at any time into Tilray common shares, with the initial conversion rate being just over 376.6 shares per $1,000 principal amount.
Yahoo Finance Live discusses a drop in shares of cannabis stock Tilray after the company revealed it's registered offering price.
Make no mistake, Nvidia has captured the imagination of Wall Street.
Investing in the cannabis industry is tricky. After merging with rival Aphria, Canadian cannabis company Tilray Brands (NASDAQ: TLRY) has grown into a bigger and better business. Tilray has always been my favorite Canadian cannabis company.
Don't look now, but SNDL (NASDAQ: SNDL) is becoming a better investment. While there's still no shortage of risk surrounding the business and the industry as a whole, SNDL is beginning to separate itself from the pack. Has it even become a better stock to buy than Tilray Brands (NASDAQ: TLRY) and Canopy Growth (NASDAQ: CGC)?
Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.
One common misconception about the stock market is that you need a large sum of money to begin investing. A small amount of money invested in growth stocks in various sectors will not only diversify your portfolio but also help it grow over time. Cannabis company Tilray Brands (NASDAQ: TLRY) and biotech company Exelixis (NASDAQ: EXEL) are two examples of outstanding growth stocks that you can buy for $20.
Tilray Brands (NASDAQ: TLRY), based in Ontario, has been my favorite among Canadian cannabis companies. In a highly competitive industry, the company implemented some smart growth strategies that favored it. Tilray's long-term prospects remain appealing.
Tilray Brands (NASDAQ: TLRY) -- and anyone considering being one of its shareholders -- should take a few hints from Anheuser-Busch InBev (NYSE: BUD) about how to become a globally relevant marijuana and alcohol company. After all, the maker of Bud Light knows a thing or two about running a brand-driven business. In particular, there are three things that Tilray is struggling with that it'll need to do if its stock is going to be worth buying in the future.
On April 10, Tilray Brands (NASDAQ: TLRY) advanced the consolidation of the marijuana industry one step further when it announced that it was acquiring Hexo, an underperforming Canadian cannabis operator. The move should leave the company with a credible claim to being the largest marijuana business in Canada, and it will contribute to Tilray's reputation as being one of the more acquisition-hungry competitors. There are a few things that shareholders likely aren't thrilled about with Tilray's latest purchase, which is expected to close in June.
Regardless of whether you're willing to take on risk or not and whether you're willing to be patient and hold a stock for years, top Canadian cannabis retailer Tilray Brands (NASDAQ: TLRY) just isn't a company worth taking a chance on. Tilray's latest earnings results only solidify why this is an all-around bad buy. Tilray reported its third-quarter earnings this month, and its net loss for the period ending Feb. 28 was a mammoth $1.2 billion.
AMC Entertainment (NYSE: AMC), SNDL (NASDAQ: SNDL), Netflix (NASDAQ: NFLX), Editas Medicine (NASDAQ: EDIT), and Tilray Brands (NASDAQ: TLRY) are some of the more popular stocks among retail investors. With the exception of Editas Medicine, all of them appear on the Top 100 most popular list among users of the Robinhood Markets trading platform.
Tilray CEO Irwin Simon joined Yahoo Finance Live to discuss the challenging cannabis market, acquisition plans, and inflation challenges. Tilray Brands, Inc., held their Q3 2023 earnings call on Tuesday, April 11. Tilray announced on Monday, April 10, that it plans to buy Hexo for a total of around $56 million in an all-stock transaction. The deal is expected to close in June 2023. Key video highlights: 00:00:05 - Simon on cannabis market challenges 00:00:32 - Simon on Hexo acquisition 00:01:15 - Simon on keys to a deal 00:02:15 - Simon on global impact 00:02:30 - Simon on inflation challenges
Tilray Brands (NASDAQ: TLRY) shook up the cannabis sector with its third-quarter fiscal 2023 earnings report last night. As of 11:15 a.m. ET, Tilray shares were lower by 7.1%, while Hexo stock was plunging by 26.5%. The moves were spurred by the announcement of a deal for Tilray to acquire Hexo in an all-stock transaction.
Yahoo Finance Live’s Brad Smith breaks down the decline in stock for Tilray Brands, Inc.
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Tilray announced after the market closed on Monday that it plans to buy Hexo for a total of around $56 million in an all-stock transaction. The deal is expected to close in June 2023 but must first clear regulatory hurdles and win approval from Hexo shareholders. Shares of Tilray have plunged more than 50% over the past 12 months.
While the top- and bottom-line numbers for Tilray Brands, Inc. (TLRY) give a sense of how the business performed in the quarter ended February 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tilray Brands, Inc. (TLRY) delivered earnings and revenue surprises of 20% and 2.72%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Shares of the craft cannabis company Organigram Holdings (NASDAQ: OGI) were up by 5.98% on heavy volume as of 2:49 p.m. ET Monday afternoon. Organigram and fellow Canadian pot titan Tilray Brands (NASDAQ: TLRY) are both set to report their latest fiscal results this week. While Tilray will report its fiscal 2023 Q3 earnings after market close today, Organigram is scheduled to reveal its fiscal 2023 Q2 earnings after the closing bell on Tuesday.
Industry headwinds still present a major challenge.
Tilray Brands, Inc. (TLRY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $2.53, moving +0.4% from the previous trading session.